Hansoh Pharma drug meets trial endpoints, shares jump
Shares of Hansoh Pharmaceutical Group rose 4.3% to HK$35.76, their highest level since September 9, after the company said its phase III clinical trial of HS-10374 in treatment of moderate-to-severe plaque psoriasis met co-primary and multiple secondary endpoints. The drug demonstrated a favourable safety and tolerability profile.
76, the stock's highest level since September 9, after the company said a phase III clinical trial of HS-10374 for moderate-to-severe plaque psoriasis met its co-primary endpoints and multiple secondary endpoints and showed a favourable safety and tolerability profile. The company said it will begin communications with the relevant regulatory authority to prepare a new drug application in China in the near term. The stock was on track for its biggest one-day percentage gain since September 14. 6%, while the Hang Seng Biotech Index is up 16%.